Sign In
Buy KRYS
$340.21
-3.22 (-0.94%)
At Close: Jun 23, 2026
3 Biotech Firms With Major Potential Catalysts in the Coming Months
05:35pm, Tuesday, 23'rd Jun 2026
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future.
3 Biotech Firms With Major Potential Catalysts in the Coming Months
10:31am, Sunday, 21'st Jun 2026
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future.
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead
01:30am, Thursday, 18'th Jun 2026
Moderna is racing towards important clinical and regulatory catalysts. Krystal Biotech still has a large market to address in its core area.
Is the Options Market Predicting a Spike in Krystal Biotech Stock?
01:00pm, Friday, 05'th Jun 2026
Investors need to pay close attention to KRYS stock based on the movements in the options market lately.
Krystal Biotech Stock Soars 16% in Three Months: Here's Why
11:31am, Thursday, 04'th Jun 2026
KRYS shares climb 16% in three months as Vyjuvek revenues jump 32%, pipeline programs advance and a nearly $1B cash pile fuels confidence.
Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?
12:30pm, Wednesday, 03'rd Jun 2026
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock
10:51am, Tuesday, 26'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
08:00am, Monday, 18'th May 2026
VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan VYJUVEK is the first geneti
Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:40pm, Wednesday, 13'th May 2026
Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
This Profitable Biotech Stealthily Climbs Into A Buy Zone
02:15pm, Monday, 11'th May 2026
This genetic disorder treatment developer's stock hit a buy point after the biotech's first-quarter earnings report last week.
Krystal Biotech: Vyjuvek Is Not The Primary Asset
06:10am, Sunday, 10'th May 2026
Krystal Biotech leverages its HSV-1 gene delivery platform, with VYJUVEK generating strong cash flow and 95% gross margins since FDA approval. KRYS is rated Buy, justified by a robust pipeline—espec
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
08:00am, Thursday, 07'th May 2026
PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conferen
Krystal Biotech: A Q1 Earnings Beat With Multiple Catalysts In 2026 And 2027
08:49am, Wednesday, 06'th May 2026
Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%. KRYS's robust balance sheet ($823M cash and negligible debt) and disciplin
Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results
02:19pm, Tuesday, 05'th May 2026
Krystal Biotech Inc (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.
